Status:
COMPLETED
Inhaled Iloprost for Suspected COVID-19 Respiratory Failure
Lead Sponsor:
Hamad Medical Corporation
Conditions:
COVID-19
ARDS, Human
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by the rapid onset of widespread inflammation in the lungs. ARDS is thought to be the main cause of respirator...
Detailed Description
The investigators hypothesize that inhaled prostacyclins (Iloprost in this study) may improve inflammation and oxygenation in suspected or confirmed COVID-19 patients with respiratory failure. Resear...
Eligibility Criteria
Inclusion
- Suspected or confirmed COVID-19 patient by PCR
- O2 saturation =\<92% on 5 or more l/min of O2 by NC or Face mask
- On CPAP, HFNC or Invasive ventilation
- Enrollment within 48h of onset of hypoxemia
Exclusion
- Age \<18
- Pregnancy or Positive pregnancy test at the time of screening
- Clinical evidence of left atrial hypertension or known chronic CHF
- Persistent Hypotension SBP\<85 on presentation
- Mechanical ventilation \>7 days
- Patients who received iloprost treatment for any indication within 48 hours prior to enrollment in the clinical trial or patients who were on thrombin inhibitors, or nitric oxide within the previous 24 h before study randomization are also excluded.
- Patients with contraindication for ilioprost
Key Trial Info
Start Date :
May 23 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04445246
Start Date
May 23 2020
End Date
May 31 2021
Last Update
March 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamad Medical Corporation
Doha, Qatar